Alnylam amyloidosis drug led to “small” benefits: FDA Markets September 11, 2023 [ad_1] Grandbrothers The U.S. Meals and Drug Administration (FDA) mentioned Monday that patisiran, a RNAi therapeutic developed by Alnylam Prescribed…
